Cyxone (publ) announces that Erika Samuelsson has been appointed new Chief Development Officer (CDO) in the company as of 1 September 2022. With her broad experience from roles in project management in drug development within the biotech business, Erika will be an important part of Cyxone's continued ambition to strengthen and develop the company. Erika Samuelsson holds a PhD in Immunology from Lund University and has over 20 years' experience from the Life Science field.

Erika has held senior positions at Alligator Bioscience AB, Idogen AB and most recently at Immunovia AB. She brings long experience within drug development where she has been responsible for studies in both late and early development stages. She also has extensive experience within Business Development, Alliance management and strategic communication in listed companies.

Erika will primarily be responsible for the continued non-clinical and clinical development activities, including the planned phase 2b study with Rabeximod in patients diagnosed with medium to severe rheumatoid arthritis (RA).